Wednesday, June 10, 2026
🇺🇸 FDA

pharma · TTR-mediated Amyloidosis · Hypertension · ALNY

Alnylam Netherlands

Alnylam Netherlands B.V.

Alnylam Netherlands trial registry — 90 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2002
Employees
2,826
Programs
84
Drugs
37
Patents
379
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

Alnylam Netherlands clinical trials

Registry index of 90 ClinicalTrials.gov studies linked to Alnylam Netherlands programs — each row shows trial ID, program name, phase, status, and indication.

Alnylam Netherlands trial registry — 90 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Alnylam Netherlands.

  1. ALN-APP-001 — Phase 1

    Clinical update

  2. ALN-TTRSC04-004 — Phase 3

    Clinical update

  3. ALN-AGT01-008 — Phase 3

    Clinical update

  4. ALN-TTRSC02-003 — Phase 3

    Clinical update

  5. ALN-TTRSC02-002 — Phase 3

    Clinical update

  6. ALN-TTR02-011 — Phase 3

    Clinical update

  7. ALN-5288-001 — Phase 1

    Clinical update

  8. Amvuttra 25 mg solution for injection in pre-filled syringe — Phase 3

    Clinical update

Trial registry

90 studies
  4. 2023-510137-29-01

    Mivelsiran, Placebo

    Phase 2 active small_molecule

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.